## BEBT-109

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-W423595 2050906-40-4 C <sub>27</sub> H <sub>32</sub> N <sub>8</sub> O <sub>3</sub> 516.59 EGFR JAK/STAT Signaling; Protein Tyrosine Kinase/RTK Please store the product under the recommended conditions in the Certificate of Analysis.	$ \begin{array}{c} N \\ + N \\ + N \\ - N \\ $
---	--	--

BIOLOGICAL ACTIVITY	·
DIOLOGICALACITATI	/

**Description** BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research<sup>[1]</sup>.

## REFERENCES

[1]. Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14(2):100961.

Caution: Product has not been fully validated for medical applications. For research use only.



Inhibitors

•

**Screening Libraries** 

•

Proteins